Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
11
2022
accepted:
06
02
2023
entrez:
17
2
2023
pubmed:
18
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
In the economy of therapeutic monitoring, an affordable viral marker is essential in the era of direct-acting antivirals (DAAs). We elucidated the kinetics of HCVcAg to delineate its precise role in monitoring therapeutic response. In this longitudinal study, 3208 patients were tested for HCV RNA. A total of 423 patients were started on DAAs. Treatment response and kinetics of HCVcAg/RNA were assessed in treatment-naïve (n = 383) and previously treated (n = 40) patients with follow-up for 2 years. After the initiation of DAAs, the rate of relapse was significantly higher in the previously treated group than naive group [12.5% (5/40) Vs 2% (7/383), p<0.0001]. The response rate at RVR was significantly higher with HCVcAg than RNA in both groups (p<0.02). The kinetics of HCVcAg and RNA were significantly different at ETR and SVR12 in the naïve (p<0.04), but similar at all therapeutic points in the previously treated group. The correlation between HCVcAg and RNA was good at baseline, ETR and SVR, except RVR in both groups (r>0.6; p<0.0001). Furthermore, HCV genotypes, treatment regimen, CTP (<7/≥7) and MELD (<15/≥15) did not influence the therapeutic response and the viral replication kinetics (p>0.05). It is the first longitudinal study from India shows that the response rate and kinetics of HCVcAg are comparable to HCV RNA for an extended duration, except at RVR, irrespective of the HCV genotypes, treatment regimen, and liver disease severity. Hence, HCVcAg can be considered as a pragmatic marker to monitor therapeutic response and predict relapse in the era of DAAs.
Sections du résumé
BACKGROUND
In the economy of therapeutic monitoring, an affordable viral marker is essential in the era of direct-acting antivirals (DAAs). We elucidated the kinetics of HCVcAg to delineate its precise role in monitoring therapeutic response.
METHODS
In this longitudinal study, 3208 patients were tested for HCV RNA. A total of 423 patients were started on DAAs. Treatment response and kinetics of HCVcAg/RNA were assessed in treatment-naïve (n = 383) and previously treated (n = 40) patients with follow-up for 2 years.
RESULTS
After the initiation of DAAs, the rate of relapse was significantly higher in the previously treated group than naive group [12.5% (5/40) Vs 2% (7/383), p<0.0001]. The response rate at RVR was significantly higher with HCVcAg than RNA in both groups (p<0.02). The kinetics of HCVcAg and RNA were significantly different at ETR and SVR12 in the naïve (p<0.04), but similar at all therapeutic points in the previously treated group. The correlation between HCVcAg and RNA was good at baseline, ETR and SVR, except RVR in both groups (r>0.6; p<0.0001). Furthermore, HCV genotypes, treatment regimen, CTP (<7/≥7) and MELD (<15/≥15) did not influence the therapeutic response and the viral replication kinetics (p>0.05).
CONCLUSIONS
It is the first longitudinal study from India shows that the response rate and kinetics of HCVcAg are comparable to HCV RNA for an extended duration, except at RVR, irrespective of the HCV genotypes, treatment regimen, and liver disease severity. Hence, HCVcAg can be considered as a pragmatic marker to monitor therapeutic response and predict relapse in the era of DAAs.
Identifiants
pubmed: 36800372
doi: 10.1371/journal.pone.0282013
pii: PONE-D-22-30217
pmc: PMC9937470
doi:
Substances chimiques
Antiviral Agents
0
RNA, Viral
0
Hepatitis C Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282013Informations de copyright
Copyright: © 2023 Ponnuvel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Lancet. 2019 Mar 30;393(10178):1319-1329
pubmed: 30704789
Hepatology. 2017 Jun;65(6):1810-1822
pubmed: 28170112
Aliment Pharmacol Ther. 2022 Oct;56(8):1224-1234
pubmed: 36031747
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864
pubmed: 30274834
BMC Gastroenterol. 2020 Mar 5;20(1):47
pubmed: 32138687
Gastroenterology. 2019 Jan;156(2):431-445
pubmed: 30342035
J Clin Lab Anal. 2017 May;31(3):
pubmed: 27580956
Indian J Med Microbiol. 2013 Oct-Dec;31(4):349-53
pubmed: 24064640
PLoS One. 2020 Mar 3;15(3):e0229994
pubmed: 32126125
J Virol Methods. 2009 Apr;157(1):8-14
pubmed: 19135481
PLoS One. 2021 Apr 22;16(4):e0250263
pubmed: 33886631
J Viral Hepat. 2019 Dec;26(12):1423-1430
pubmed: 31448470
J Clin Lab Anal. 2021 Jun;35(6):e23755
pubmed: 33788295
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Gastroenterology. 2019 Sep;157(3):692-704.e9
pubmed: 31078622
PLoS One. 2018 Jun 1;13(6):e0198642
pubmed: 29856885
J Hepatol. 2019 Dec;71(6):1106-1115
pubmed: 31433303
J Clin Virol. 2011 Aug;51(4):264-9
pubmed: 21621454